# Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

> **NCT01954992** · PHASE3 · RECRUITING · sponsor: **Eleison Pharmaceuticals LLC.** · enrollment: 480 (estimated)

## Conditions studied

- Metastatic Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Glufosfamide
- **DRUG:** Fluorouracil

## Key facts

- **NCT ID:** NCT01954992
- **Lead sponsor:** Eleison Pharmaceuticals LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2014-04
- **Primary completion:** 2026-06
- **Final completion:** 2026-12
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2024-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01954992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01954992, "Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01954992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*